West Pharmaceutical Services, Inc. (NYSE:WST) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

West Pharmaceutical Services, Inc. (NYSE:WST) issued its earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.01, reports. The firm had revenue of $397.60 million during the quarter, compared to analyst estimates of $406 million. West Pharmaceutical Services had a net margin of 11.42% and a return on equity of 14.02%. The business’s revenue was up 2.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.59 earnings per share. West Pharmaceutical Services updated its FY17 guidance to $2.66-2.73 EPS.

Shares of West Pharmaceutical Services (NYSE:WST) opened at 86.71 on Wednesday. The stock’s 50 day moving average is $93.44 and its 200-day moving average is $88.71. The stock has a market capitalization of $6.42 billion, a price-to-earnings ratio of 37.21 and a beta of 1.10. West Pharmaceutical Services has a 52 week low of $70.17 and a 52 week high of $99.91.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Wednesday, October 18th will be paid a dividend of $0.14 per share. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.13. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date of this dividend is Tuesday, October 17th. West Pharmaceutical Services’s payout ratio is currently 22.22%.

COPYRIGHT VIOLATION NOTICE: “West Pharmaceutical Services, Inc. (NYSE:WST) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS” was posted by BBNS and is the sole property of of BBNS. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://baseballnewssource.com/markets/west-pharmaceutical-services-inc-nysewst-announces-quarterly-earnings-results-updated/1308115.html.

A number of brokerages have recently issued reports on WST. Zacks Investment Research raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a research note on Friday, June 23rd. BidaskClub lowered shares of West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $90.18.

In related news, CFO William J. Federici sold 54,996 shares of the firm’s stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $95.45, for a total transaction of $5,249,368.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.90% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the company. Burt Wealth Advisors increased its stake in shares of West Pharmaceutical Services by 38,540.0% in the first quarter. Burt Wealth Advisors now owns 1,932 shares of the medical instruments supplier’s stock worth $158,000 after buying an additional 1,927 shares during the last quarter. Harfst & Associates Inc. purchased a new position in West Pharmaceutical Services during the first quarter valued at $186,000. CIBC Asset Management Inc purchased a new position in West Pharmaceutical Services during the second quarter valued at $223,000. Tyers Asset Management LLC increased its position in West Pharmaceutical Services by 17.6% in the first quarter. Tyers Asset Management LLC now owns 2,464 shares of the medical instruments supplier’s stock valued at $201,000 after buying an additional 368 shares in the last quarter. Finally, Cutler Group LP increased its position in West Pharmaceutical Services by 482.2% in the second quarter. Cutler Group LP now owns 2,550 shares of the medical instruments supplier’s stock valued at $241,000 after buying an additional 2,112 shares in the last quarter. 91.35% of the stock is owned by hedge funds and other institutional investors.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Earnings History for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury


Leave a Reply

 
© 2006-2017 BBNS.